Reading ORKA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ORKA free→Reading ORKA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ORKA free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, ORKA is typical. There is no valuation input available. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $68.86. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.78x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.53 → $-0.50 (+5.3% / 30d). 7 raised, 2 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 229.0% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$259.
How much price usually moves either way.
On a bad day, this stock has moved -$631.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,799.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If healthcare revenue growth speeds up, it could help Oruka's performance. This is important as the sector is currently slowing.
Confirms:Healthcare sector revenue growth rises back toward 10% or higher.
Disproves:Healthcare sector revenue growth continues to slow below 10%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ORKA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
solely because it was disclosed in the preliminary prospectus supplement relating to the Offering. This preliminary estimate is based on currently available information and is subject to revision based upon, among other things, the finalization and closing of the Company’s accounting books and records. The Company’s financial results for the three months ended March 31, 2026 are not yet finalized. The preliminary financial data included in the prospectus supplement was prepared by, and is the…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2024-Q2, 2024-Q3, 2025-Q1, 2025-Q2
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ORKA Oruka Therapeutics, Inc. | Typical Show detailsSector percentile: 44 of 100 | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
No qualifying priorities for this snapshot. Check back after the next refresh.
Why it matters: The earnings report will show if the company is still losing money. Investors will look for any signs of improvement.
Confirms:Q2 earnings show a loss greater than the previous quarter's loss.
Disproves:Q2 earnings report shows a smaller loss or a profit.
Other Events. On April 28, 2026, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), providing for the offering and sale by the Company of 9,660,000 shares of common stock, par value $0.001 per share (the “Common Sto…
Other Events. On April 27, 2026, Oruka announced results from its Phase 2a EVERLAST-A clinical trial of ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-A Phase 2a Key 16-Week Results The Phase 2a EVERLAST-A clinical trial is a randomized, double-blind, placebo-controlled study evaluating ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-A enrolled 84 patients randomized 3:1 to receive 600 mg of ORKA-001 at Weeks 0 and 4 or matching placebo. The primary endpoint is PASI 100…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (a) Resignation of Director On December 11, 2025, Cameron Turtle resigned as a member of the Board of Directors (the “Board”) of Oruka Therapeutics, Inc. (“Oruka” or the “Company”). Such resignation was not because of a disagreement with the registrant on any matter relating to Oruka’s operations, policies or practices, nor was the resignation a re…
Entry into a Material Definitive Agreement. On September 17, 2025, Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). The closing of the Private Placement occurred on September 19, 2025. Pursuant to the Purchase Agreement, the Purchasers purchased (i…